TY - JOUR T1 - 转换从静脉依前列醇到selexipag在肺动脉高血压：谨慎JF的一个字 - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.02418-2019 SP - 1902418 AU - 谷中，健一AU - Guillien，艾丽西亚AU - 苏马涅，蒂博AU - 贝尼特，贾斯汀AU - Piliero，萨科AU - 皮卡德，弗朗索瓦AU - 皮松，克里斯托夫AU - 希特博恩，奥利维尔AU - Bouvaist，海伦AU - Degano，布鲁诺Y1 - 2020年1月1日UR - HTTP：//www.qdcxjkg.com/content/early/2020/02/20/13993003.02418-2019.abstract N2 - 前列环素类似物针对前列环素途径用于治疗患者的肺动脉高压（PAH），并且由下式给出任一静脉内（IV），皮下（SC）或吸入途径[1]。依前列醇的连续IV输注已经接收到用于治疗的PAH [2]的最严重形式的最强建议，主要是因为它是被证明得到的改善的存活在随机对照研究中只有特定PAH-药物[3]。由于其IV给药有关的缺点，依前列醇优先提供给年轻的，高风险的患者[2]。对于PAH患者在纽约心脏协会（NYHA）功能类（FC）III / IV与严重的血流动力学障碍，依前列醇可以与内皮素受体拮抗剂（ERA）和磷酸二酯酶5型（PDE-5）抑制剂相结合，实现持续的临床和血流动力学功效[4,5] .FootnotesThis手稿最近已经接受了在欧洲呼吸杂志出版。据审稿，并通过我们的制作团队排版之前在这里其已接受的形式出版。经过这些生产工艺齐全，作者已经批准了造成证据，文章将在网上移动到ERJ最新一期。 Please open or download the PDF to view this article.Conflict of interest: Dr Yanaka has nothing to disclose.Conflict of interest: Dr Guillien has nothing to disclose.Conflict of interest: Dr Soumagne has nothing to disclose.Conflict of interest: Dr Benet has nothing to disclose.Conflict of interest: Dr Piliero has nothing to disclose.Conflict of interest: Dr Picard has nothing to disclose.Conflict of interest: Dr Pison reports grants and personal fees from GlaxoSmithKline, personal fees from Novartis Pharma, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, outside the submitted work.Conflict of interest: Dr Sitbon reports personal fees from Arena Pharmaceuticals, personal fees and non-financial support from Actelion Pharmaceuticals, personal fees from Acceleron Pharmaceuticals, grants and personal fees from Bayer HealthCare, non-financial support from GlaxoSmithKline, personal fees from Gossamer Bio, grants and personal fees from Merck, outside the submitted work.Conflict of interest: Dr Bouvaist reports grants and non-financial support from GlaxoSmithKline, grants and non-financial support from Bayer HealthCare, personal fees and non-financial support from Actelion Pharmaceuticals, outside the submitted work.Conflict of interest: Dr Degano reports personal fees and non-financial support from Actelion Pharmaceuticals, non-financial support from Bayer HealthCare, grants, personal fees and non-financial support from Novartis Pharma, personal fees from Chiesi, personal fees from GlaxoSmithKline, personal fees from Menarini, outside the submitted work. ER -